The National Foundation for Cancer Research’s translational research focus is on supporting critical “Proof of Concept” pre-clinical and Phase I clinical studies. These efforts yield data that help indicate whether an experimental cancer drug, diagnostic, screen, or preventive tool is likely to be successful in later-stage clinical trials: Phases II and III.
NFCR conducts its pre-clinical and Phase I clinical trial support initiatives in partnership with our venture philanthropy affiliate, the AIM-HI Accelerator Fund. Established in 2019 with an initial grant from our organization, AIM-HI is a 501(C)(3) U.S. non-profit organization whose purpose is to accelerate the translation of cancer drug discoveries by investing in seed-stage oncology technology companies.
